History of Clinical Research
Formal clinical development of bremelanotide was launched by the company Palatin Technologies in the early 2000s, initially as a nasal spray. In later phases of research, concerns emerged about this route's effect on blood pressure, leading to a shift toward a subcutaneous injectable form as a more controllable alternative. This shift wasn't merely a matter of administration convenience — it responded to a specific safety signal identified in earlier phases of clinical testing.
Bremelanotide's clinical program proceeded in parallel across two populations — in men, with a focus on erectile dysfunction, and in women, with a focus on hypoactive sexual desire disorder (HSDD). Both research tracks relied on the same underlying mechanism of action but progressed at different paces and reached different levels of formal conclusion — while the women's program advanced through two large-scale Phase III trials, research in men remained at the Phase II stage. This difference in the depth of clinical data is important to keep in mind when comparing what is known about PT-141's effects across the sexes.
| Research Phase | Description | Key Finding |
|---|---|---|
| Early studies in men | Diamond et al., Urology — double-blind, placebo-controlled crossover study in men with erectile dysfunction, intranasal administration | Significant improvement in erection quality and intercourse success, including in a subgroup of men in whom prior sildenafil treatment had failed |
| Shift to injectable form | Development moves from nasal spray to subcutaneous injection | Response to a blood-pressure-related safety signal identified with the nasal form |
| Dose-finding in women | Clayton et al., Journal of Sexual Medicine — Phase IIb study in premenopausal women with hypoactive sexual desire disorder (HSDD) | Characterized the relationship between dose, efficacy, and nausea rates; informed the protocol for the subsequent Phase III program |
| Pivotal Phase III trials | Kingsberg et al. — two identically designed trials in women with HSDD, subcutaneous administration over 24 weeks | The largest and best-controlled clinical program with bremelanotide in humans to date |
How PT-141 Works
PT-141 acts as an agonist of melanocortin receptors — a family of five G-protein-coupled receptors (MC1R through MC5R) that regulate a wide range of distinct processes in the body. While some of these receptors relate to skin pigmentation or the regulation of energy metabolism, the MC3R and MC4R receptors play a key role in regulating sexual function, and it is these that PT-141 primarily targets. The degree to which PT-141 binds each receptor varies — it is not a purely selective compound binding exclusively to one receptor type, but a molecule with a strong preference for MC3R/MC4R over other members of this receptor family.
| Receptor | Main Location in the Body | Primary Function |
|---|---|---|
| MC1R | Skin, melanocytes | Regulation of pigmentation (melanin production) |
| MC2R | Adrenal cortex | Regulation of cortisol production (the ACTH receptor) |
| MC3R | Hypothalamus and other brain regions | Modulates energy homeostasis; in the sexual circuit, functions more as a "brake" on the signaling pathway |
| MC4R | Hypothalamus and adjacent brain regions | Key role in regulating sexual function, appetite, and the autonomic nervous system |
| MC5R | Exocrine glands | Regulation of exocrine gland secretion (e.g., sebaceous glands) |
Unlike PDE5 inhibitors (such as sildenafil), which act peripherally on blood flow, PT-141 acts centrally — directly on brain signaling pathways linked to sexual desire and arousal. That's why PT-141 is studied more as an agent influencing desire and arousal rather than mechanical blood flow.
More recent research also suggests that MC4R activation by bremelanotide may influence oxytocin release in brain regions linked to social behavior and pair bonding — a 2023 paper (Dolan et al.) explored this connection as a supplementary mechanism alongside the direct effect on sexual desire. This is a relatively new direction in melanocortin system research, extending beyond pure sexual pharmacology toward a broader understanding of social behavior at the neurobiological level.
Pharmacokinetically, bremelanotide is designed for subcutaneous administration with a relatively fast onset of effect — in clinical trials, the assessed effect on desire and arousal appeared within tens of minutes of administration. This is typical of peptides intended for "as-needed" use, as opposed to drugs meant for regular daily dosing, where a long-term stable level of the active compound in the body is expected instead. This pharmacokinetic profile matches how bremelanotide was administered in clinical trials — as a single dose before anticipated sexual activity, not as part of ongoing treatment.
Clinical Studies in Women: What the Data Show
A key milestone was the Phase IIb study (Clayton et al., 2016), which tested multiple dose levels in premenopausal women with hypoactive sexual desire disorder (HSDD), seeking the optimal balance between efficacy and adverse effects, chiefly nausea. This study informed the protocol for the subsequent Phase III program.
Two key, identically designed Phase III trials (Kingsberg et al., 2019) together enrolled approximately 1,200 premenopausal women, who self-administered a subcutaneous injection of bremelanotide or placebo over 24 weeks. Both trials met their co-primary endpoints — improved sexual desire and reduced associated distress compared with placebo. This remains the largest and best-controlled clinical program with bremelanotide in humans to date.
Clinical Studies in Men: What the Data Show
In men, PT-141 has a longer but less formally completed research history. Diamond et al. published, in the journal Urology, a double-blind, placebo-controlled crossover study in men with erectile dysfunction that showed significant improvement in erection quality and intercourse success — including in a subgroup of men in whom prior sildenafil treatment had failed.
Follow-up research included a Phase II study combining bremelanotide with a PDE5 inhibitor in men who respond insufficiently to PDE5 inhibitor treatment alone. Clinical development in the male population overall rests on a smaller body of data than exists for women.
An interesting aspect of the research in men is that bremelanotide's effect on erection appeared in trials even without visual sexual stimulation — confirming the central, rather than peripheral, nature of the effect. PDE5 inhibitors, by contrast, require some degree of sexual arousal as a precondition to work at all, since they don't generate arousal themselves — they only facilitate the physiological response to it. This mechanistic difference is why PT-141 is also studied as a potential add-on to PDE5 inhibitors in men for whom PDE5 inhibitor treatment alone isn't sufficient.
Safety and Adverse Effects
Bremelanotide's safety profile is, thanks to two completed Phase III trials, among the best-documented in the entire category of peptides discussed on this site. Adverse events were reported in 76.6% of women in the bremelanotide arm versus 58.2% in the placebo arm — a difference largely explained by predictable pharmacological effects of the compound.
| Adverse Effect | Bremelanotide | Placebo | Note |
|---|---|---|---|
| Nausea | 40.0% | 1.3% | The main tolerability issue; typically peaks 30–60 minutes post-injection and resolves within 3 hours |
| Flushing | Reported in a minority but meaningful share of participants | Lower incidence | Usually mild and transient |
| Transient blood pressure increase | Present in most users | Absent | A well-characterized, predictable effect in trials |
| Hyperpigmentation (gums, face) | Approximately 1% of participants | Rare | Related to partial residual MC1R activity; according to available data, may not fully resolve after discontinuation |
Nausea is the main factor driving early treatment discontinuation among trial participants. Given its effect on blood pressure, the compound is excluded in trials for people with uncontrolled hypertension or known cardiovascular disease.
It's worth noting that the rate of adverse effects, particularly nausea, was clearly dose-dependent in trials — as the dose increased, so did both the frequency and intensity of nausea, a common pattern for compounds acting on the central nervous system. This dose-tolerability relationship was the central focus of the Phase IIb study mentioned above, which sought the dose with the best ratio of efficacy to adverse effects.
Summary
PT-141 (bremelanotide) is a melanocortin peptide that primarily targets the MC3R and MC4R receptors linked to the regulation of sexual desire and arousal, with a mechanism of action distinct from peripherally acting drugs such as PDE5 inhibitors. Clinical data in women rest on two extensive Phase III trials with a well-documented safety profile (nausea, transient blood pressure increase, hyperpigmentation in rarer cases). In men, encouraging but less formally concluded Phase II data exist. Anyone wanting to track further research in the male population should watch the results of the ongoing combination program with PDE5 inhibitors, which remains at the clinical testing stage. The gap in the depth of available data between the female and male populations remains one of the main limitations of the current state of knowledge about this compound, as does the generally more limited body of long-term safety data outside controlled clinical settings.
Sources
- Diamond LE, et al. "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction." Urology, 2006.
- Clayton AH, et al. "Bremelanotide for female sexual dysfunction: mechanism of action and clinical evidence." Journal of Sexual Medicine, 2018.
- Kingsberg SA, et al. Phase III trials of bremelanotide for hypoactive sexual desire disorder. Journal of Women's Health / Obstetrics & Gynecology, 2019.
- Ückert S, et al. "Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies." Review, 2014.
- Dolan et al. Study on MC4R activation, oxytocin release, and social behavior, 2023.